echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > 【Heavy】6 essentials of perioperative comprehensive management of hip and knee replacement in hemophilia

    【Heavy】6 essentials of perioperative comprehensive management of hip and knee replacement in hemophilia

    • Last Update: 2022-11-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the Guidelines for the Perioperative Management of Hip and Knee Replacement in Hemophilic Osteoarthropathy1, jointly compiled by the Joint Surgery Group of the Orthopedic Branch of the Chinese Medical Association and the China Hemophilia Collaboration Group, were released, which further standardized the perioperative management of hip and knee replacement in hemophilia osteoarthropathy and provided a reference
    for related clinical work.


    In this issue, the editor summarizes 6 essentials of the recommendations in the guide and shares
    them with you.


    Essence 1 The situation is grim - 36% of hemophilia A patients in China have hemophilic osteoarthropathy 01



    80% of bleeding occurs in the joints of patients with hemophilia, in turn in the knee, elbow, ankle and hip joints, and in the second and third decades of the disease, 90% of patients can develop hemophilic osteoarthropathy
    .

    02

    In the study published by the China Hemophilia Collaboration Group in 2021, a total of 17,779 patients with hemophilia A were registered from 166 hospitals in China from 2007 to 2019, and a total of 3,997 patients were recorded related to joint status, of which 61% had joint bleeding, 36% had osteoarthropathy, and the number of patients suffering from osteoarthropathy of the knee joint ranked first
    .


    Essence 2 The right medicine - choose the right type of surgery and surgical team01



    Patients with end-stage hemophilic arthropathy who do not respond to conservative management: artificial arthroplasty is preferred, with knee replacement and hip arthroplasty
    being the most common.

    02

    Surgical team selection: The success of orthopedic surgery relies on the collaboration of a multidisciplinary team (Figure 1).


    Figure 1 Surgical team members

    03

    Preoperative multidisciplinary comprehensive assessment: the operation should be performed in a hospital with qualifications in hemophilia diagnosis and treatment centers and integrated management centers, as well as experience in hemophilia orthopedic surgery; Multidisciplinary and adequate preoperative assessment is performed to minimize perioperative complications and ensure the safety and efficacy
    of surgery.


    Essentials 3 Be prepared – a comprehensive assessment should be made before surgery and a detailed management plan should be developed01



    Evaluation: A detailed assessment of the patient's symptoms, signs, joint status, etc.
    (Figure 2).


    Figure 2 Preoperative evaluation

    02

    Management: comprehensive management
    of coagulation factors, inhibitors, rehabilitation treatment, surgical planning, etc.


    • Coagulation factor selection: FVIII coagulation factor is preferred in hemophilia A, including recombinant or hematogenous products; Recombinant or bloodborne FIX coagulation factor
      is preferred in hemophilia B.

    • Inhibitor management: inhibitors
      must be routinely tested preoperatively.
      Elective surgery for patients with hemophilia with inhibitors involves a variety of treatment options, and elective surgery
      such as hip and knee replacement is not recommended for these patients.
      If surgery is necessary, multidisciplinary treatment is recommended and individualized treatment
      is discussed.

    • Rehabilitation: Before hip and knee replacement, the rehabilitation team needs to discuss the actual rehabilitation plan and goals with the hemophilia multidisciplinary team and the patient, and reasonably manage the patient's surgical expectations
      .

    • Surgical planning: When there are surgical indications for multiple lesions at the same time, it is recommended to choose a first-stage or staged surgery
      according to the size of the operation, the difficulty of the operation, the patient's tolerance and the experience of the orthopedic surgeon.


    Essence 4 Comprehensive protection - real-time monitoring during surgery should be carried out to select the appropriate treatment modality01



    Tranexamic acid: in patients with hemophilia undergoing hip and knee replacement, perioperative tranexamic acid may reduce factor doses of replacement therapy and reduce surgery-related blood
    loss.

    02

    Drains: based on the available evidence, it is recommended that indwelling drains be placed after hip and knee replacement in patients with hemophilia
    .
    After 3-4h of clipping, the drainage is opened in a non-negative pressure state, and it is removed 48-72h after surgery, and the intraarticular blood
    is drained under negative pressure before extraction.

    03

    Anesthesia and analgesia: general anesthesia is recommended for hip and knee arthroplasty, and neck diseases affecting anesthesia should be excluded before surgery, and cervical spine imaging, cardiopulmonary function, and neurology should be
    performed if necessary.
    Prophylactic analgesia, multimodal analgesia
    .


    Essence 5 Continuous help - postoperative complications such as bleeding and infection should be reduced01



    Coagulation factor management: the replacement treatment of coagulation factors can be described in the table below:


    Note: *Drug-restricted regimens may increase the risk of perioperative bleeding

    02

    Anemia management: patients with hemoglobin less than 70 g/L or hemoglobin less than 100 g/L with symptoms of anemia (fatigue, palpitations, pallor, tachycardia, shortness of breath due to anemia) should receive blood transfusion
    .

    03

    Bleeding management: postoperative hematoma, it is recommended to detect inhibitors, increase the concentration of coagulation factors, use RICE rule to improve bleeding during bleeding, resume rehabilitation physiotherapy in time after bleeding control, and if necessary, hematoma aspiration and compression bandaging can be performed under coagulation factor replacement therapy
    .

    04

    Thrombosis management: if patients with hemophilia A continue to receive adequate factor replacement therapy after surgery, prophylactic anticoagulation is recommended until the end of
    factor replacement therapy.

    05

    Infection prevention: surgery should be performed with appropriate coagulation factor replacement therapy and strict sterile conditions, with control of infection predisposing factors and correct application of prophylactic antibiotics
    .

    06

    Rehabilitation: early postoperative rehabilitation should be started 24 hours after surgery or after drainage tube removal; The patient is again functionally assessed before the start of rehabilitation training, and based on the evaluation results, the rehabilitation team formulates training steps and plans, which are carried out
    under the protection of adequate coagulation factor replacement therapy.


    Essence 6 tailor-made - PK guides perioperative coagulation factor medication 01



    Non-bleeding period before surgery: FVIII or FIX 30~50 IU/kg can be pre-transfused, and blood is collected 4h, 24h and 48h after infusion to determine the FVIII level
    .
    Subsequently, according to the population PK model combined with the calculation tool of the maximum posterior Bayesian method, the PK parameters of the individual patient were obtained for the formulation of subsequent dosing regimens
    .

    02

    Intraoperative medication adjustment: According to the preoperative PK parameters and the target FVIII level, special calculation software is used to formulate the preoperative starting dose, and after the initial dose is given, the peak concentration of 15-30min after the end of the transfusion of coagulation factors can be detected if the conditions are available to guide the intraoperative medication adjustment
    .

    03

    During postoperative hospitalization: Trough concentration monitoring
    of coagulation factors can be performed intermittently.
    If the coagulation factor does not reach the target concentration, the dosing can be adjusted according to the weight-based calculation formula, or the dosing regimen
    can be adjusted by recalculating the individual PK parameters.


    The calculation of the above individual PK parameters and the formulation of dosing regimens can be completed by special calculation software, among which the recombinant human coagulation factor VIII dose calculation software for injection (referred to as PK software) has been approved by the National Medical Products Administration for hemophilia A patients aged 16 years and above (body weight 45kg and above) receiving rAHF-PFM treatment2
    .


    In addition, during postoperative rehabilitation, centers or patients with conditions can use PK calculation software (such as PK software) to guide treatment
    .


    summary


    • Hip and knee replacement for hemophilic osteoarthropathy should be managed perioperatively in a standardized period:

    • A comprehensive assessment should be made before surgery, and coagulation factors and inhibitors should be managed and surgical planning should be done;

    • Do a good job of hemostasis and analgesic management during surgery;

    • Postoperative training for the prevention and rehabilitation of anemia, bleeding, blood clots and infections;

    • Post-discharge follow-up and continuation of coagulation factor management while rehabilitation is conducted

    • In addition to the weight of the perioperative coagulation factor dosing regimen, PK guidance can also be used to formulate an individualized dosing regimen, after understanding the patient's PK characteristics before surgery, according to the PK parameters and target factor levels, the special calculation software can be used to determine the dose
      of administration.


    References:

    1.
    Tong Peijian, Weng Xisheng, Yang Renchi, et al.
    Guidelines for perioperative management of hip and knee replacement in hemophilic osteoarthropathy in China.
    Chinese Journal of Osteosurgery and Joint Surgery, 2022, 15(7): 481-490.

    2.
    style="text-align:justify;line-height: 1.
    75em;">


    Approval number: VV-MEDMAT-76597

    Approval period: 10/20/2022

    Expires: 10/19/2024


    statement

    This information is intended to help healthcare professionals better understand the latest developments
    in related disease areas.
    This platform does not agree with its description and views on the content of the information released, but only provides more information
    .
    If copyright issues are involved, please contact us and we will deal with it
    as soon as possible.


    The information provided in this information is not in any way a substitute for professional medical advice and should not be construed as medical advice
    .
    If such information is used for purposes other than information, this platform, the author and Takeda shall not be liable
    in connection with it.


    Review: MOLY Typesetting: MOLY Execution: MOLY
    This platform is designed to deliver more medical information
    to healthcare professionals.
    The content published on this platform cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
    .
    If such information is used for purposes other than understanding medical information, this platform does not assume relevant responsibilities
    .
    The content published by this platform does not mean that it agrees with its description and views
    .
    If copyright issues are involved, please contact us and we will deal with it
    as soon as possible.



    Poke "Read Original" to see more

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.